Philippe J. Zamor

Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4–5 chronic kidney disease (the C-SURFER study): a combination phase 3 study

David Roth, David R. Nelson, Annette Bruchfeld et al. · The Lancet · 2015 · 666 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +15

Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION): a non-randomised, open-label trial

Jürgen K. Rockstroh, Mark Nelson, Christine Katlama et al. · The Lancet HIV · 2015 · 306 citations

Pharmacy, Infectious Diseases, Pharmacotherapy +13

Successful treatment of chronic hepatitis C with pegylated interferon in combination with ribavirin in a methadone maintenance treatment program

Alain H. Litwin, Kenneth A. Harris, Shadi Nahvi et al. · Journal of Substance Abuse Treatment · 2008 · 104 citations · Full text

Pharmacy, Clinical Pharmacy, Pharmacotherapy +15

Efficacy and safety of glecaprevir/pibrentasvir in renally impaired patients with chronic HCV infection

Eric Lawitz, Robert Flisiak, Manal Abunimeh et al. · Liver International · 2019 · 64 citations

Medicine, Infectious Diseases, Pharmacotherapy +17

Patient preferences for colorectal cancer screening: how does stool DNA testing fare?

Paul C. Schroy, Subodh K. Lal, Julie T. Glick et al. · PubMed · 2007 · 62 citations

Medicine, Oncology, Cancer Screening +16